
Thursday, May 18, 2017 3:32:35 PM
Now any licensing deal is more likely to involve a lot of hard bargaining over a longer time frame since it puts the potential licensee in more of an adversarial position. (Or so one might theorize.)
Maybe another vote will be tried again at some point...

Liked By
Spread the love. Be the first to like this post!
Recent AVXL News
- Current Report Filing (8-k) • Edgar (US Regulatory) • 05/24/2023 08:44:14 PM
- Quarterly Report (10-q) • Edgar (US Regulatory) • 05/09/2023 08:32:49 PM
- Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results • GlobeNewswire Inc. • 05/09/2023 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023 • GlobeNewswire Inc. • 05/02/2023 11:30:00 AM
- Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension • GlobeNewswire Inc. • 05/01/2023 11:30:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 04/25/2023 11:30:00 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 04/14/2023 10:08:18 AM
- Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023 • GlobeNewswire Inc. • 04/10/2023 11:00:00 AM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 04/04/2023 09:32:52 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 04/04/2023 09:32:09 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 04/04/2023 09:31:56 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 04/04/2023 09:31:41 PM
- Statement of Changes in Beneficial Ownership (4) • Edgar (US Regulatory) • 04/04/2023 09:31:30 PM
- ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia • GlobeNewswire Inc. • 03/30/2023 11:00:00 AM
- Nightfood, Inc. (OTCQB: NGTF) now in Sonesta International Hotels Multiple Brands • InvestorsHub NewsWire • 03/13/2023 11:35:55 AM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 03/13/2023 10:02:21 AM
- Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics • GlobeNewswire Inc. • 03/09/2023 12:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/09/2023 04:11:12 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 02/09/2023 03:26:43 PM
- Current Report Filing (8-k) • Edgar (US Regulatory) • 02/07/2023 10:21:29 PM
- Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) • Edgar (US Regulatory) • 02/07/2023 10:17:10 PM
- Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results • GlobeNewswire Inc. • 02/07/2023 12:00:00 PM
- Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial • GlobeNewswire Inc. • 02/02/2023 12:00:00 PM
- Amended Statement of Ownership (sc 13g/a) • Edgar (US Regulatory) • 01/31/2023 06:59:54 PM
- Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023 • GlobeNewswire Inc. • 01/31/2023 12:00:00 PM
CGrowth Capital Consolidates Lithium Tenement Portfolio in Tanzania Amid Renewed Mining Confidence • CGRA • May 25, 2023 11:05 AM
Interactive Strength Inc. d/b/a FORME Launches European Expansion Plan by Focusing on Strategic Partnership with SIGNA Sports United • TRNR • May 24, 2023 10:14 AM
Nextech3D.ai Game-Changing Generative-AI CAD 3D Design Studio Toggle3D.ai Primed For $7 Million June IPO • NTAR • May 24, 2023 10:00 AM
Kaya Holdings, Inc.'s V.P. Bryan Arnold Among First Ten (10) State Licensed Psilocybin Facilitators in U.S.A. • KAYS • May 24, 2023 9:48 AM
ILUS Confirms Its First Quarter of 2023 Results • ILUS • May 23, 2023 9:34 AM
SKYX Set to Join Russell 2000® and Russell 3000® Indexes • SKYX • May 23, 2023 8:56 AM